Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

 

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Background:
Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This is a Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.

Objectives:

Determine the maximum tolerated dose of erlotinib in patients with solid tumors and hepatic or renal dysfunction.
Determine the pharmacokinetics of this drug in these patients.

Location and Contact Information:
California
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States; Recruiting
Alan Paul Venook, MD 415-476-2201
District of Columbia
Lombardi Cancer Center, Washington, District of Columbia, 20007, United States;
Recruiting
Edward P. Gelmann, MD 202-687-2490
gelmanne@georgetown.edu

Illinois
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Recruiting
Gini F. Fleming, MD 773-702-6712

Iowa
Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242-1009, United States;
Recruiting
Gerald H. Clamon, MD 319-356-1932

Maryland
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, 21201, United States;
Recruiting
Martin J. Edelman, MD 410-328-2703
medelman@umm.edu

New Hampshire
Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
Lionel D. Lewis, MD 603-650-6300

New York
Long Island Jewish Medical Center, New Hyde Park, New York, 11040, United States;
Recruiting
Marc Laurence Citron, MD 718-470-8930
citron@lij.edu

North Shore University Hospital, Manhasset, New York, 11030, United States;
Recruiting
Daniel R. Budman, MD 516-562-8958

North Carolina
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States;
Recruiting
David Duane Hurd, MD 336-716-2088
dhurd@wfubmc.edu

Ohio
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, 43210-1240, United States;
Recruiting
Clara D. Bloomfield, MD 614-293-7518
bloomfield-1@medctr.osu.edu
Study chairs or principal investigators
Antonius Miller, MD, Study Chair
Comprehensive Cancer Center of Wake Forest University